Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

29.72 -0.74 (-2.43%)

Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	840,525
Open	30.84
Bid (Size)	29.71 (1)
Ask (Size)	30.40 (2)
Prev. Close	30.46
Today's Range	29.55 - 32.00
52wk Range	16.54 - 50.40
Shares Outstanding	58,102,949
Dividend Yield	48.52%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

October 29, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

September 30, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+5.1%	+5.1%
1 Month	-39.4%	-39.4%
3 Month	-0.8%	-0.8%
6 Month	+0.7%	+0.7%
1 Year	+10.2%	+10.2%

More News

Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation

September 27, 2025

Via MarketMinute

Earnings Scheduled For May 7, 2025

May 07, 2025

Via Benzinga

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

August 25, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session

August 11, 2025

Via Benzinga

Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket

August 11, 2025

Via Benzinga

LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People

August 01, 2025

Via Benzinga

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

July 31, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Lenz (LENZ) Q2 Revenue Jumps 604%

July 31, 2025

Via The Motley Fool

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

July 30, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

July 28, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

July 07, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Present at Upcoming Investor Conferences

May 27, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

May 09, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 07, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

May 06, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session

May 02, 2025

Via Benzinga

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

April 30, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

April 01, 2025

From Climb Bio, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session

March 19, 2025

Via Benzinga

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

March 19, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For March 19, 2025

March 19, 2025

Via Benzinga

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

March 11, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Host Commercial Day on April 15, 2025

March 03, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is LENZ Therapeutics, Inc. - Common Stock publicly traded?

Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?

LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?

The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market

What is the current price of LENZ Therapeutics, Inc. - Common Stock?

The current price of LENZ Therapeutics, Inc. - Common Stock is 29.72

When was LENZ Therapeutics, Inc. - Common Stock last traded?

The last trade of LENZ Therapeutics, Inc. - Common Stock was at 10/31/25 04:00 PM ET

What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?

The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 1.73B

How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?

LENZ Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.